Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
miscellaneous service companies in Europe:
Genmab A/S
of Denmark
(2018
sales of 3.03 billion Danish Kroner [US$447.05 million]
of which 100%
was Pharmaceticals),
Bachem Holding AG
of Switzerland
(282.50 million Swiss Francs [US$283.35 million]
of which 89%
was Active Pharmaceutical Ingredients), and
AddLife AB
which is
based in Sweden
(2.48 billion Swedish Kronor [US$253.12 million]
of which 58%
was LabTech).
Sales Analysis.
Galapagos NV reported sales of 317.85 million Euro (US$350.82 million)
for the
year ending
December of 2018.
This
represents
an
increase of 103.9%
versus 2017, when the company's sales were 155.92 million Euro.
This was the third consecutive year of growth at Galapagos NV.
Sales of R&d saw an increase
of
135.6% in 2018, from
118.26 million Euro to 278.67 million Euro.